Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Multiple myeloma
BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans · Blood 148 (Supplement 1)
The meeting is in December. Regular abstracts have been public since 4 Nov 2026 but the Blood supplement was not in Crossref on 11 Nov, so ASH abstracts here come from web research. Late-breaking abstracts are embargoed until 7 Dec and are not shown.
Headline and verified abstracts
30 abstracts found by Parallel web research on 2026-11-11 and verified: 30 checked on the source page. Rows that could not be verified were dropped. Titles and metadata only; abstract text is not stored.
- 115OralAnitocabtagene autoleucel following induction therapy in newly diagnosed multiple myeloma: Early safety, response, and MRD Results from the phase 2 GEM-anitofirst studyMaria-Victoria Mateos JrGEM-anitofirstanitocabtagene autoleucelVerified on source pageonlineprogram.hematology.org
- 116Oral
- 117Oral
- 118OralDeep and durable responses achieved with CB-011, an off-the-shelf CAR-T cell therapy, for heavily pretreated patients with relapsed/refractory multiple myeloma (CaMMouflage trial)Adriana RossiCaMMouflageCB-011Verified on source pageonlineprogram.hematology.org
- 119Oral
- 120OralGPRC5D expression and locus integrity in relapsed/refractory multiple myeloma treated with arlocabtagene autoleucel in a first-in-human Phase 1 trialSafiyyah Ziyadarlocabtagene autoleucelVerified on source pageonlineprogram.hematology.org
- 265Oral
- 266Oral
- 267OralSonrotoclax in combination with dexamethasone and daratumumab for t(11;14) relapsed/refractory multiple myeloma: Preliminary safety and efficacy results from the phase 1b/2 BGB-11417-105 studyBinod DhakalBGB-11417-105sonrotoclaxdexamethasonedaratumumabVerified on source pageonlineprogram.hematology.org
- 268OralSafety and preliminary efficacy of vemzatatug vedotin (AZD0305), a first-in-class novel antibody-drug conjugate targeting GPRC5D, in patients with relapsed/refractory multiple myeloma: Results from a phase 1/2 studyAmrita Krishnanvemzatatug vedotin (AZD0305)Verified on source pageonlineprogram.hematology.org
- 269Oral
- 270OralFirst-in-human phase 1/2a study of pamlectabart tismanitin (HDP-101), an amanitin-based BCMA-targeting antibody-drug conjugate (ADC): Recommended phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed/refractory multiple myeloma (RRMM)Marc-Steffen Steffen RaabHDP-101-01pamlectabart tismanitin (HDP-101)Verified on source pageonlineprogram.hematology.org
- 421OralFirst- and only-in-class CD38xBCMAxCD3 trispecific T-cell engager ISB-2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM)Binod DhakalTRIgnite-1ISB-2001 (ABBV-2001)Verified on source pageonlineprogram.hematology.org
- 422OralSustained MRD-negativity with teclistamab-based treatment in transplant-eligible, newly diagnosed multiple myeloma in the phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trialNiels WeinholdGMMG-HD10/DSMM-XX (MajesTEC-5)teclistamabVerified on source pageonlineprogram.hematology.org
- 423OralENTRUST-IFM/PETHEMA: Preliminary results of the phase 2 portion of a phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of Etentamig and daratumumab in frail transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)Salomon ManierENTRUST-IFM/PETHEMAetentamigdaratumumabVerified on source pageonlineprogram.hematology.org
- 424Oral
- 425OralCevostamab consolidation following BCMA CAR T cell therapy: primary endpoint analysis of the phase 2 “STEM” (Sequential T Cell-Engagement for Myeloma) trialAdam D. CohenSTEM (Sequential T Cell-Engagement for Myeloma)cevostamabVerified on source pageonlineprogram.hematology.org
- 426OralPrimary Analysis of the phase 3 randomized MonumenTAL-6 study of teclistamab (Tec) plus talquetamab (Tal) or Tal plus pomalidomide (Pom) vs investigator's choice of elotuzumab, Pom and dexamethasone (EPd) or Pom, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and 1–4 prior lines of therapy (LOT)Verified on source pageonlineprogram.hematology.org
- 931OralSingle-cell profiling reveals Tumor–Marrow biological penetrance and actionable target programs in high-risk multiple myelomaJunia Vieira dos SantosVerified on source pageonlineprogram.hematology.org
- 2796PosterMelflufen plus dexamethasone for relapsed/refractory multiple myeloma, including patients previously exposed to immunotherapy: Real-world outcomes from a spanish registry (amhh)David Martínez-Campuzano SrmelflufendexamethasoneVerified on source pageonlineprogram.hematology.org
- 5740PosterSecond primary malignancies (SPM) after transplantation for multiple myeloma: Risk continues to increase beyond 10 yearsVismay DeshaniVerified on source pageonlineprogram.hematology.org
- 5741Poster
- 5742Poster
- 5743PosterThe double dip: Identifying Critical Time Points for cytopenia after bispecific antibody therapyKristina NasrVerified on source pageonlineprogram.hematology.org
- 5744PosterHematologic improvement following weekly intravenous immunoglobulin (IVIG) for prolonged cytopenias after T-cell redirecting therapy for multiple myelomaMichelle Rudshteyn Korostinintravenous immunoglobulin (IVIG)Verified on source pageonlineprogram.hematology.org
- 5745PosterSafety and outcomes of combined radiation therapy with bispecific antibodies in relapsed/refractory multiple myelomaPatrick GouldVerified on source pageonlineprogram.hematology.org
- 5746Poster
- 5747Poster
- 5748Poster
- 5749Poster
Indexed in Crossref
The ASH Annual Meeting 2026 supplement (Blood 148 (Supplement 1)) was not in Crossref when last checked on 11 Nov 2026. The verified abstracts above come from web research instead.